Annexin A1 Is Associated with Adverse Clinical Outcomes in Patients with COVID-19

Annexin A1 Is Associated with Adverse Clinical Outcomes in Patients with COVID-19

Severe coronavirus disease 2019 (COVID-19) is characterized by hyperinflammation, vascular damage, and hypercoagulability. Insufficient responses of Annexin A1 (AnxA1), a pro-resolving inhibitor of neutrophil infiltration and activation, might contribute to a severe course of the disease. We longitu...

Full description

Bibliographic Details
Main Authors: Matthias H. Busch, Sjoerd A. M. E. G. Timmermans, Joop P. Aendekerk, Renée Ysermans, Jean Amiral, Jan G. M. C. Damoiseaux, Chris P. Reutelingsperger, Pieter van Paassen
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Journal of Clinical Medicine
Subjects:
COVID-19
Annexin A1
hyperinflammation
adverse outcomes
Online Access:https://www.mdpi.com/2077-0383/11/24/7486

Internet

https://www.mdpi.com/2077-0383/11/24/7486

Similar Items